IL13RA2 and neoplasm: A safety and efficacy trial of CAR T cell therapy in GBM with IL-13Ra2 as the tumor marker was performed on a group of three patients who had a post-resection intracranial infusion, followed by a trial of post-resection direct intratumoral infusion followed intraventricular infusion [61, 62•].